Skip to content
Medical Learning Institute Inc
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Community Collective: Obesity
NMPD Series
Obstructive Sleep Apnea Series
A Quick Dose of CE
Contact Us
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Community Collective: Obesity
NMPD Series
Obstructive Sleep Apnea Series
A Quick Dose of CE
Contact Us
Medical Learning Institute Inc
Main Menu
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Community Collective: Obesity
NMPD Series
Obstructive Sleep Apnea Series
A Quick Dose of CE
Contact Us
Pre-Test for P22082-05
Please enable JavaScript in your browser to complete this form.
What is the most diagnosed leukemia in the US?
AML
CLL/SLL
ALL
CML
On average, what percentage of patients with CLL/SLL need treatment upon diagnosis?
10%–30%
30%–50%
50%–70%
70%–90%
What is the least common upfront treatment option for CLL/SLL?
FCR
Ibrutinib ± obinutuzumab/rituximab/venetoclax
Acalabrutinib ± obinutuzumab
Venetoclax + obinutuzumab
A 70-year-old patient with CLL is very fearful about COVID-19 and would prefer to avoid time in the hospital; however, says she would be okay with it for short periods, if necessary. Which of these regimens would you recommend?
Ibrutinib
Acalabrutinib + obinutuzumab
FCR
Chlorambucil + obinutuzumab
A 67-year-old patient with CLL and a TP53 mutation prefers a fixed-duration regimen. Which of the following would you recommend?
Venetoclax + obinutuzumab
FCR
Chlorambucil + obinutuzumab
Bendamustine + rituximab
A young, fit, patient with CLL with high tumor burden is going to start on a fixed-duration ibrutinib + venetoclax regimen. What AE will you be most concerned about in the beginning of therapy?
Atrial fibrillation
Infections
Arthralgia
TLS
A Black patient with CLL and TP53 mutation is starting acalabrutinib and obinutuzumab in the next few days. Which of these AEs would you counsel him to monitor for?
TLS
Severe neutropenia
HBV reactivation
Diarrhea
A Black patient newly diagnosed with CLL is feeling unsure about whether to pick a fixed- or continuous-duration regimen. She want your advice. How would you approach her in a way that she feels comfortable with the decision?
Go over the treatment option that would be best for the patient, highlighting the reasons why this is the correct choice.
Explain the difference between disease control and deep remission and the pros and cons of both and assess how these fit with the patient’s values and preferences.
Explore and compare the benefits and risks of the treatment options covered by Medicaid, taking into consideration the patient’s values and preferences.
Reach a shared decision based on the toxicity profile of the various drugs available in the pharmacy.
When trying to build trust with a patient, what is one of the most important things you can do?
Establish your credibility
Keep an open mind
Tell the patient you have all the time in world
Encourage participation and listen attentively
Submit
Post Test From Live Meeting
Boston Post-Assessment (P22082-05)
Please enable JavaScript in your browser to complete this form.
A 70-year-old patient with CLL is very fearful about COVID-19 and would prefer to avoid time in the hospital; however, says she would be okay with it for short periods, if necessary. Which of these regimens would you recommend?
Ibrutinib
Acalabrutinib + obinutuzumab
FCR
Chlorambucil + obinutuzumab
A 67-year-old patient with CLL and a TP53 mutation prefers a fixed-duration regimen. Which of the following would you recommend?
Venetoclax + obinutuzumab
FCR
Chlorambucil + obinutuzumab
Bendamustine + rituximab
A young, fit, patient with CLL with high tumor burden is going to start on a fixed-duration ibrutinib + venetoclax regimen. What AE will you be most concerned about in the beginning of therapy?
Atrial fibrillation
Infections
Arthralgia
TLS
A Black patient with CLL and TP53 mutation is starting acalabrutinib and obinutuzumab in the next few days. Which of these AEs would you counsel him to monitor for?
TLS
Severe neutropenia
HBV reactivation
Diarrhea
A Black patient newly diagnosed with CLL is feeling unsure about whether to pick a fixed- or continuous-duration regimen. She want your advice. How would you approach her in a way that she feels comfortable with the decision?
Go over the treatment option that would be best for the patient, highlighting the reasons why this is the correct choice.
Explain the difference between disease control and deep remission and the pros and cons of both and assess how these fit with the patient’s values and preferences.
Explore and compare the benefits and risks of the treatment options covered by Medicaid, taking into consideration the patient’s values and preferences.
Reach a shared decision based on the toxicity profile of the various drugs available in the pharmacy.
When trying to build trust with a patient, what is one of the most important things you can do?
Establish your credibility
Keep an open mind
Tell the patient you have all the time in world
Encourage participation and listen attentively
Submit
Scroll to Top
